This move is archived. Current quotes and coverage live on the stock page.
Get BCT alerts:
Briacell Therapeutics Corp's shares surged by nearly 2% in the latest trading session, reflecting positive investor sentiment.
Briacell Therapeutics Corp (BCT.TO) experienced a notable gain of 1.89% in the last trading session, closing at CA$4.31. This uptick marks a positive shift for the biotech firm, which has been navigating a challenging market landscape. Investors are keenly watching the company's developments as it continues to innovate in the field of personalized immunotherapy.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$42.37M
52W high
$20.40
52W low
$3.68
1W change
-5.62%
Beta
1.53
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 310.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+310.7% Upside
Current Price
C$4.87
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
81.8%
Annualized
90-Day Vol
87.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.82
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.17 | C$3.90 โ C$6.85 |
| 60 trading days | C$5.49 | C$3.68 โ C$8.18 |
| 90 trading days | C$5.82 | C$3.57 โ C$9.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: With a market cap of CA$37.2 million and no current dividend yield, Briacell remains a speculative investment. However, the recent share price increase could signal renewed interest in its therapeutic advancements.
Briacell Therapeutics Corp gains 1.89% in one day
The stock closed at CA$4.31, reflecting a market cap of CA$37.2 million, indicating the company's ongoing struggle for profitability in a competitive market.
Bull case
The recent rise in Briacell's stock likely reflects growing investor confidence in its innovative therapies, especially after some recent clinical successes. As the company continues to develop its personalized immunotherapy solutions, potential breakthroughs could attract even more interest and investment.
Bear case
Despite the gains, Briacell still faces significant challenges, including a lack of profitability and ongoing market volatility in the biotech sector. Investors should be cautious, as the stock's performance can be highly sensitive to clinical trial outcomes and regulatory approvals.
Advertisement
Stock Performance Overview
Briacell Therapeutics Corp's stock has shown resilience with a 1.89% increase in the last trading session. Closing at CA$4.31, this movement indicates a positive shift in investor sentiment, particularly as the company continues to focus on its innovative therapies.
Market Position and Future Outlook
With a market cap of CA$37.2 million, Briacell is still in a precarious position within the biotech landscape. Investors are advised to keep a close eye on the company's upcoming developments, particularly regarding its personalized immunotherapy products, which could dictate future stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
